EMA/594885/2020  
Memantine LEK 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3 
amended 
on 
IB/0010 
C.I.2.a - Change in the SPC, Labelling or PL of a 
20/10/2020 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
the MAH 
R/0009 
Renewal of the marketing authorisation. 
09/11/2017 
08/01/2018 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Memantine LEK in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
II/0007/G 
This was an application for a group of variations. 
27/10/2016 
n/a 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
IB/0008 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
28/06/2016 
24/05/2017 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
Memantine LEK  
EMA/594885/2020 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0006 
C.I.8.a - Introduction of or changes to a summary of 
12/05/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
N/0005 
Minor change in labelling or package leaflet not 
24/04/2014 
03/06/2014 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0004 
C.I.8.a - Introduction of or changes to a summary of 
08/10/2013 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IB/0003/G 
This was an application for a group of variations. 
24/06/2013 
03/06/2014 
SmPC, 
Labelling and 
PL 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Memantine LEK  
EMA/594885/2020 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0001 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
24/06/2013 
03/06/2014 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IAIN/0002/G 
This was an application for a group of variations. 
24/05/2013 
03/06/2014 
Annex II and 
PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.2.b.1 - Change to batch release arrangements 
and quality control testing of the FP - Not including 
batch control/testing 
Memantine LEK  
EMA/594885/2020 
Page 4/4 
 
 
 
 
 
 
 
 
 
 
